Table of Contents
ISRN Pathology
Volume 2011, Article ID 598131, 6 pages
http://dx.doi.org/10.5402/2011/598131
Research Article

Triple Negative Breast Carcinoma: A Comparative Study between Breast Lesion and Lymph Node Metastases: A Preliminary Study

1Servei de Patologia, Hospital Universitari Sant Joan de Reus, Institut d'Investigació Sanitaria Pere Virgili (IISPV), Universitat Rovira i Virgili, Reus, 43206 Tarragona, Spain
2Epidemiología, Estadística i Bioinformàtica, Institut d'Investigació Sanitaria Pere Virgili (IISPV), Universitat Rovira i Virgili, Reus, 43007 Tarragona, Spain

Received 18 May 2011; Accepted 14 June 2011

Academic Editors: A. Gocht, A. Pagani, T. Shien, and A. Stringer

Copyright © 2011 David Parada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits of human breast tumours,” Nature, vol. 406, no. 6797, pp. 747–752, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Sørlie, C. M. Perou, R. Tibshirani et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869–10874, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Sørlie, R. Tibshirani, J. Parker et al., “Repeated observation of breast tumor subtypes in independent gene expression data sets,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8418–8423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. B. G. Haffty, Q. Yang, M. Reiss et al., “Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5652–5657, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. T. O. Nielsen, F. D. Hsu, K. Jensen et al., “Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma,” Clinical Cancer Research, vol. 10, no. 16, pp. 5367–5374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. L. A. Carey, C. M. Perou, C. A. Livasy et al., “Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study,” Journal of the American Medical Association, vol. 295, no. 21, pp. 2492–2502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Calza, P. Hall, G. Auer et al., “Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients,” Breast Cancer Research, vol. 8, no. 4, article no. R34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Fan, D. S. Oh, L. Wessels et al., “Concordance among gene-expression-based predictors for breast cancer,” New England Journal of Medicine, vol. 355, no. 6, pp. 560–569, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Moinfar, “Is 'basal-like' carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes,” Pathobiology, vol. 75, no. 2, pp. 119–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. F. M. Blows, K. E. Driver, M. K. Schmidt et al., “Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies,” PLoS Medicine, vol. 7, no. 5, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Rakha and J. S. Reis-Filho, “Basal-like breast carcinoma: from expression profiling to routine practice,” Archives of Pathology and Laboratory Medicine, vol. 133, no. 6, pp. 860–868, 2009. View at Google Scholar · View at Scopus
  13. E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis, “Basal-like breast cancer: a critical review,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2568–2581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Tanner, P. Järvinen, and J. Isola, “Amplification of HER-2/neu and Topoisomerase IIα in primary and metastatic breast cancer,” Cancer Research, vol. 61, no. 14, pp. 5345–5348, 2001. View at Google Scholar · View at Scopus
  15. A. Vincent-Salomon, M. Jouve, P. Genin et al., “HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process,” Cancer, vol. 94, no. 8, pp. 2169–2173, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. R. J. Broom, P. A. Tang, C. Simmons et al., “Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer,” Anticancer Research, vol. 29, no. 5, pp. 1557–1562, 2009. View at Google Scholar · View at Scopus
  17. J. S. Koo, W. Jung, and J. Jeong, “Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site,” Tumori, vol. 96, no. 3, pp. 424–432, 2010. View at Google Scholar · View at Scopus